181220-75-7

Usage

Uses

Used in Organic Synthesis:
Tert-butyl 2-iodo-1H-imidazole-1-carboxylate is utilized as a synthetic intermediate for the preparation of various organic compounds. Its reactivity, particularly due to the iodine atom, allows for efficient coupling reactions in the synthesis of pharmaceuticals, agrochemicals, and other specialty chemicals.
Used in Pharmaceutical Research:
In the pharmaceutical industry, tert-butyl 2-iodo-1H-imidazole-1-carboxylate serves as a key building block for the development of novel drug candidates. Its unique structure and reactivity enable the creation of new molecules with potential therapeutic properties, contributing to the discovery of innovative treatments for various diseases and conditions.
Used in the Creation of Complex Molecules:
Tert-butyl 2-iodo-1H-imidazole-1-carboxylate is employed as a structural component in the assembly of more complex molecules. Its incorporation into larger molecular frameworks can lead to the development of advanced materials with specific properties, such as improved stability, enhanced solubility, or targeted reactivity, which can be applied across various chemical and materials science applications.

Upstream product

• 3034-62-6 2-iodo-1H-imidazole 
• 24424-99-5 di-tert-butyl dicarbonate 

Downstream Products

• 1313759-20-4 1-tert-butoxycarbonyl-2-((4-methoxyphenyl)ethynyl)-1H-imidazole 

Relevant academic research and scientific papers

Novel and selective TLR7 antagonists among the imidazo[1,2- a]pyrazines, Imidazo[1,5- a]quinoxalines, and Pyrazolo[1,5- a]quinoxalines Series

The Toll-like receptors (TLRs) 7 and 8 play an important role in the immune system activation, and their agonists may therefore serve as promising candidate vaccine adjuvants. However, the chronic immune activation by excessive TLR stimulation is a hallmark of several clinically important infectious and autoimmune diseases, which warrants the search for TLR antagonists. In this study, we have synthesized and characterized a variety of compounds belonging to three heterocyclic chemical series: imidazo[1,2-a]pyrazine, imidazo[1,5-a]quinoxaline, and pyrazolo[1,5-a]quinoxaline. These compounds have been tested for their TLR7 or TLR8 agonistic and antagonistic activities. Several of them are shown to be selective TLR7 antagonists without any TLR7 or TLR8 agonistic activity. The selectivity was confirmed by a comparative ligand-docking study in TLR7 antagonist pocket. Two compounds of the pyrazolo[1,5-a]quinoxaline series (10a and 10b) are potent selective TLR7 antagonists and may be considered as promising starting points for the development of new therapeutic agents.

FACTOR XIa INHIBITORS

The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein.

FRICTIONLESS MOLECULAR ROTARY MOTORS

A rotaxane consisting of a cucurbituril and an uncharged guest molecule, having low or null affinity therebetween is provided as well as processes for providing the same. Various uses as energy converters (“frictionless” molecular motors), biochips and biosensors using the same are also provided.